Market Overview

Senseonics to Participate in the Canaccord Genuity Growth Conference


Senseonics Holdings, Inc. (NYSE:SENS), a medical technology
company focused on the development and commercialization of
transformative glucose monitoring products, today announced the company
plans to participate in the upcoming Canaccord Genuity Growth Conference
in Boston, MA.

Senseonics' management is scheduled to present Thursday, August 9, 2018
at 1:30pm ET. Interested parties may access a live and recorded webcast
of the presentation on the "Investor Relations" section of the company's
website at

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics' Eversense System is a long-term, implantable device,
which includes a small sensor, smart transmitter and mobile application.
Based on fluorescence sensing technology, the sensor is designed to be
inserted subcutaneously and communicate with the smart transmitter to
wirelessly transmit glucose levels to a mobile device. After insertion,
the sensor is designed to continually and accurately measure glucose
levels. The Eversense System is approved in the United States and
indicated for 90 days of continuous use and the Eversense XL System is
approved in EMEA and indicated for up to 180 days of continuous use. For
more information on Senseonics, please visit

View Comments and Join the Discussion!